Cover Image
市場調查報告書

NASH(非酒精性脂肪性肝炎)生物標記市場分析:產品類型,終端用戶,地區別預測

NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type (Serum, Hepatic Fibrosis, Apoptosis, Oxidative Stress), By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, & Other), And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 544800
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
NASH(非酒精性脂肪性肝炎)生物標記市場分析:產品類型,終端用戶,地區別預測 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type (Serum, Hepatic Fibrosis, Apoptosis, Oxidative Stress), By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, & Other), And Segment Forecasts, 2014 - 2025
出版日期: 2017年07月28日 內容資訊: 英文 100 Pages
簡介

本報告提供NASH(非酒精性脂肪性肝炎)生物標記市場相關調查,提供整體市場趨勢,各產品類型·終端用戶·地區別詳細趨勢,市場規模的變化與預測,推動市場要素及阻礙因素分析,競爭情形,主要企業簡介等系統性資訊。

第1章 調查手法

第2章 摘要整理

第3章 NASH(非酒精性脂肪性肝炎)生物標記市場

  • 市場區隔和範圍
  • 推動市場要素分析
  • 市場阻礙因素分析
  • 市場滲透度·成長率預測
  • SWOT分析
  • 波特的五力分析

第4章 NASH(非酒精性脂肪性肝炎)生物標記市場:各產品類型

  • 市場趨勢分析:各產品類型
  • 血清標記
  • 肝纖維化標記
  • 細胞凋亡標記
  • 氧化壓力標記
  • 其他

第5章 NASH(非酒精性脂肪性肝炎)生物標記市場:各終端用戶

  • 市場趨勢分析:各終端用戶
  • 製藥·醫藥品開發受託機關(CRO)
  • 醫院
  • 診斷檢驗設施
  • 學術研究機關

第6章 NASH(非酒精性脂肪性肝炎)生物標記市場:各地區

  • 各地區的市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第7章 競爭情形

  • 策略組成架構
  • 市場進入
  • 企業簡介
目錄
Product Code: GVR-1-68038-518-2

The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to reach USD 2.09 billion by 2025, according to a new report by Grand View Research, Inc. Increasing incidence of chronic liver diseases is expected to propel the demand for NASH biomarkers over the forecast period. The National Health and Nutrition Examination Survey recently found that approximately 30% of Nonalcoholic Fatty Liver Diseases (NAFLD) occurred in the U.S. alone. This disease remains undiagnosed, as a liver can remain fatty without any change in its function. However, it can progress into a serious condition, known as nonalcoholic steatosis that may result in liver failure. NASH is characterized by inflammation and irreversible cell death.

Rising demand for non-invasive diagnostic tools for detection of NASH is another driver of market. Traditionally, liver biopsy is performed to diagnose NAFLD and its degenerative condition, that is, NASH. This technique is expensive and invasive in nature. This disadvantage has led to the development of noninvasive and cost-efficient diagnostic techniques such as biomarker tests. It is observed that many key companies spent significantly on research and development activities to introduce novel biomarker tests. These factors are expected to propel NASH biomarkers market in the coming years.

The drug manufacturers are focusing on tapping unmet medical needs for treatment of NASH to capture additional market share. Strategic collaborations, expansion in developing geographies, and technological advancements are some of the key strategies adopted by existing market players.

Further Key Findings From the Study Suggest:

Serum biomarkers held majority of the revenue share as of 2016 owing to its high efficacy in NASH diagnosis

Gamma-glutamyl transferase is the serum biomarker that is usually higher in patients with fatty liver diseases, resulting in liver failure

Increasing list of patients awaiting liver transplantation is a major contributing factor for the growing demand of noninvasive biomarker tests over the forecast period

Pharmaceutical and contract research industry dominate the end-use segment owing to ample availability of R&D funding and ongoing research projects for the development NASH drugs

Industry participants are focusing on development of cost-effective solutions, thereby increasing R&D activities for development of novel technologies

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country wise market: Base estimates
  • 1.2 Global market: CAGR calculation
  • 1.3 Region based segment share calculation
  • 1.4 Research Scope & Assumptions
  • 1.5 List of Data Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 NASH Biomarkers Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing prevalence of chronic diseases
    • 3.2.2 Increasing demand for non invasive diagnostics for NASH biomarkers
    • 3.2.3 Rising investment by government and private organizations in R&D for NASH biomarkers therapeutics
  • 3.3 Market Restraint Analysis
    • 3.3.1 Side-effects and risks associated with NASH therapeutics
  • 3.4 Penetration & Growth Prospect Mapping
  • 3.5 NASH biomarkers- SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's

Chapter 4 NASH Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1 NASH Biomarkers Market: Type Movement Analysis
  • 4.2 Serum Biomarkers
    • 4.2.1 Serum biomarkersmarket, 2014 - 2025 (USD Million)
  • 4.3 Hepatic Fibrosis Biomarkers
    • 4.3.1 Hepatic fibrosis biomarkers market, 2014 - 2025 (USD Million)
  • 4.4 Apoptosis Biomarkers
    • 4.4.1 Apoptosis biomarkers market, 2014 - 2025 (USD Million)
  • 4.5 Oxidative Stress Biomarkers
    • 4.5.1 Oxidative stress biomarkers market, 2014 - 2025 (USD Million)
  • 4.6 Others
    • 4.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 5 NASH Biomarkers Market: End-use Estimates & Trend Analysis

  • 5.1 NASH biomarkersMarket: End-use Movement Analysis
  • 5.2 Pharma & CRO Industry
    • 5.2.1 Pharma & CRO industry market, 2014 - 2025 (USD Million)
  • 5.3 Hospitals
    • 5.3.1 Hospitalsmarket, 2014 - 2025 (USD Million)
  • 5.4 Diagnostic Labs
    • 5.4.1 Diagnostic Labs market, 2014 - 2025 (USD Million)
  • 5.5 Academic Research Institutes
    • 5.5.1 Academic research institutes Market, 2014 - 2025 (USD Million)

Chapter 6 NASH biomarkers Market: Regional Estimates & Trend Analysis, by Type, and End-use

  • 6.1 NASH biomarkersMarket Share by Region, 2016 & 2025
  • 6.2 North America
    • 6.2.1 North America NASH biomarkers market, by country, 2014 - 2025 (USD Million)
    • 6.2.2 North America NASH biomarkers market, by type, 2014 - 2025 (USD Million)
    • 6.2.3 North America NASH biomarkersmarket, by end-use, 2014 - 2025 (USD Million)
    • 6.2.4 U.S.
      • 6.2.4.1 U.S. NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.2.4.2 U.S. NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.2.5 Canada
      • 6.2.5.1 Canada NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.2.5.2 Canada NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe NASH biomarkers market, by country, 2014 - 2025 (USD Million)
    • 6.3.2 Europe NASH biomarkers market, by type, 2014 - 2025 (USD Million)
    • 6.3.3 Europe NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.3.4 Germany
      • 6.3.4.1 Germany NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.3.4.2 Germany NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.3.5 UK
      • 6.3.5.1 UK NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.3.5.2 UK NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia PacificNASH biomarkers market, by country, 2014 - 2025 (USD Million)
    • 6.4.2 Asia Pacific NASH biomarkers market, by type, 2014 - 2025 (USD Million)
    • 6.4.3 Asia Pacific NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.4.4 Japan
      • 6.4.4.1 Japan NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.4.4.2 Japan NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.4.5 China
      • 6.4.5.1 China NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.4.5.2 China NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.4.6 India
      • 6.4.6.1 India NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.4.6.2 India NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America NASH biomarkers market, by country, 2014 - 2025 (USD Million)
    • 6.5.2 Latin America NASH biomarkers market, by type, 2014 - 2025 (USD Million)
    • 6.5.3 Latin America NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.5.4 Brazil
      • 6.5.4.1 Brazil NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.5.4.2 Brazil NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
    • 6.5.5 Mexico
      • 6.5.5.1 Mexico NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.5.5.2 Mexico NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • 6.6 MEA
    • 6.6.1 MEA NASH biomarkersmarket, by country, 2014 - 2025 (USD Million)
    • 6.6.2 MEA NASH biomarkersmarket, by type, 2014 - 2025 (USD Million)
    • 6.6.3 MEA NASH biomarkersmarket, by end-use, 2014 - 2025 (USD Million)
    • 6.6.4 South Africa
      • 6.6.4.1 South Africa NASH biomarkers market, by type, 2014 - 2025 (USD Million)
      • 6.6.4.2 South Africa NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy Framework
  • 7.2 Market Participation
  • 7.3 Company Profiles
    • 7.3.1 GENFIT SA
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Products benchmarking
      • 7.3.1.4 Geographic footprint
      • 7.3.1.5 Strategic initiatives
    • 7.3.2 Gilead Sciences, Inc. (GILD)
      • 7.3.2.1 Company overview
      • 7.3.2.2 Financial performance
      • 7.3.2.3 Products benchmarking
      • 7.3.2.4 Geographic footprint
      • 7.3.2.5 Strategic initiatives
    • 7.3.3 AstraZeneca
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Products benchmarking
      • 7.3.3.4 Geographic footprint
      • 7.3.3.5 Strategic initiatives
    • 7.3.4 Novartis AG
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Products benchmarking
      • 7.3.4.4 Geographic footprint
      • 7.3.4.5 Strategic initiatives
    • 7.3.5 Bristol-Myers Squibb Company
      • 7.3.5.1 Company overview
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Products benchmarking
      • 7.3.5.4 Geographic footprint
      • 7.3.5.5 Strategic initiatives
    • 7.3.6 Allergan Plc
      • 7.3.6.1 Company overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Products benchmarking
      • 7.3.6.4 Geographic footprint
      • 7.3.6.5 Strategic initiatives
    • 7.3.7 Novo Nordisk A/S
      • 7.3.7.1 Company overview
      • 7.3.7.2 Financial performance
      • 7.3.7.3 Products benchmarking
      • 7.3.7.4 Geographic footprint
      • 7.3.7.5 Strategic initiatives
    • 7.3.8 Boehringer Ingelheim
      • 7.3.8.1 Company overview
      • 7.3.8.2 Financial performance
      • 7.3.8.3 Products benchmarking
      • 7.3.8.4 Geographic footprint
      • 7.3.8.5 Strategic initiatives
    • 7.3.9 Pfizer Inc
      • 7.3.9.1 Company overview
      • 7.3.9.2 Financial performance
      • 7.3.9.3 Products benchmarking
      • 7.3.9.4 Geographic footprint
      • 7.3.9.5 Strategic initiatives

List of Tables

  • TABLE 1 Factors used in segment share estimation
  • TABLE 2 North America NASH biomarkers market, by country, 2014 - 2025 (USD Million)
  • TABLE 3 North America NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 4 North America NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 5 U.S. NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 6 U.S. NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 7 Canada NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 8 Canada NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 9 Europe NASH biomarkers market, by country, 2014 - 2025 (USD Million)
  • TABLE 10 Europe NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 11 Europe NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 12 Germany NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 13 Germany NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 14 UK NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 15 UK NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 16 Asia Pacific NASH biomarkers market, by country, 2014 - 2025 (USD Million)
  • TABLE 17 Asia Pacific NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 18 Asia Pacific NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 19 JapanNASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 20 JapanNASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 21 China NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 22 China NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 23 India NASH biomarkers market, by Type, 2014 - 2025 (USD Million)
  • TABLE 24 India NASH biomarkers market, by End-use, 2014 - 2025 (USD Million)
  • TABLE 25 Latin America NASH biomarkersmarket, by country, 2014 - 2025 (USD Million)
  • TABLE 26 Latin AmericaNASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 27 Latin AmericaNASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 28 Brazil NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 29 Brazil NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 30 Mexico NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 31 Mexico NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 32 MEA NASH biomarkersmarket, by country, 2014 - 2025 (USD Million)
  • TABLE 33 MEA NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 34 MEA NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)
  • TABLE 35 South Africa NASH biomarkers market, by type, 2014 - 2025 (USD Million)
  • TABLE 36 South Africa NASH biomarkers market, by end-use, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Penetration & Growth Prospect Mapping
  • FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8 Porter's Five Forces Analysis
  • FIG. 9 NASH biomarkers market, Type outlook:Key takeaways
  • FIG. 10 NASH biomarkers market: Type movement analysis
  • FIG. 11 Serum biomarkers market, 2014 - 2025 (USD Million)
  • FIG. 12 Hepatic fibrosis biomarkers market, 2014 - 2025 (USD Million)
  • FIG. 13 Apoptosis biomarkers market, 2014 - 2025 (USD Million)
  • FIG. 14 Oxidative stress biomarkers market, 2014 - 2025 (USD Million)
  • FIG. 15 Others market, 2014 - 2025 (USD Million)
  • FIG. 16 NASH biomarkers market, End-use outlook:Key takeaways
  • FIG. 17 NASH biomarkers market: End-use movement analysis
  • FIG. 18 Pharma & CRO industry market, 2014 - 2025 (USD Million)
  • FIG. 19 Hospitals market, 2014 - 2025 (USD Million)
  • FIG. 20 Diagnostic Labs market, 2014 - 2025 (USD Million)
  • FIG. 21 Academic research institutes market, 2014 - 2025 (USD Million)
  • FIG. 22 Regional market place: Key takeaways
  • FIG. 23 Regional outlook, 2016& 2025
  • FIG. 24 Strategy framework
  • FIG. 25 Market participation and categorization
Back to Top